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Abstract. Co-existing depression worsens Alzheimer’s disease (AD) pathology. Neutrophil gelatinase-associated lipocalin
(NGAL) is a newly identified (neuro)inflammatory mediator in the pathophysiologies of both AD and depression. This study
aimed to compare NGAL levels in healthy controls, AD without depression (AD–D), and AD with co-existing depression
(AD+D) patients. Protein levels of NGAL and its receptors, 24p3R and megalin, were assessed in nine brain regions from
healthy controls (n = 19), AD–D (n = 19), and AD+D (n = 21) patients. NGAL levels in AD–D patients were significantly
increased in brain regions commonly associated with AD. In the hippocampus, NGAL levels were even further increased in
AD+D subjects. Unexpectedly, NGAL levels in the prefrontal cortex of AD+D patients were comparable to those in controls.
Megalin levels were increased in BA11 and amygdala of AD+D patients, while no changes in 24p3R were detected. These
findings indicate significant differences in neuroimmunological regulation between AD patients with and without co-existing
depression. Considering its known effects, elevated NGAL levels might actively promote neuropathological processes in AD
with and without depression.
Keywords: 24p3R, Alzheimer’s disease, depression, hippocampus, inflammation, lipocalin 2, megalin, NGAL
INTRODUCTION
Alzheimer’s disease (AD) is a multifactorial
neurodegenerative disorder [1]. Apart from the
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9713 GZ Groningen, The Netherlands. Tel.: +3150 3612401; Fax:
+3150 3611707; E-mail: p.p.de.deyn@umcg.nl.
classical amyloid- (A) cascade hypothesis and
tau hypothesis of AD, mounting evidence has led
to the understanding that more mechanisms are
involved in the etiology of AD [2–4]. For exam-
ple, another important factor in the pathophysiology
of AD is neuroinflammation, characterized by pro-
inflammatory processes in the brain [5–7]. Increased
pro-inflammatory processes have been proposed as
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a biological constituent linking AD and depression
[8, 9]. Depression is a neuropsychiatric symptom that
is frequently present in AD [10] and associated with
an increased risk for the progression of mild cognitive
impairment (MCI) to AD [11–14]. Furthermore, AD
patients with co-existing depression (AD+D) have a
poorer prognosis than AD patients without depres-
sion (AD–D) [15–17]. Interestingly, AD+D patients
present aggravated A and tau pathology in the hip-
pocampus, as compared to AD–D patients [17, 18].
Several studies have demonstrated that a low grade
inflammatory environment is present in the brain and
blood in depressed [19–21] and AD patients [5–7].
However, immune regulation in AD patients with
co-existing symptoms of depression is poorly under-
stood and existing studies are limited.
Recently a pro-inflammatory mediator called neu-
trophil gelatinase-associated lipocalin (NGAL) was
identified to be involved in the pathophysiology of
both AD and depression [22, 23]. NGAL is also
known as lipocalin 2, 24p3, uterocalin, and sidero-
calin, and belongs to the lipocalin family of small
hydrophobic proteins [24–27]. NGAL acts via its
two known receptors, megalin (also known as Lrp2)
and 24p3R (also known as SLC22A17 and BOCT1)
[28, 29]. NGAL functions as an acute phase protein
in the innate immune response and plays an impor-
tant role in the defense against certain bacteria [30].
It exerts various important functions in the central
nervous system, depending on the cellular environ-
ment, as recently reviewed by Jha and colleagues
[31]. NGAL mRNA and protein are expressed in
very low levels in the brain under normal physio-
logical conditions [32, 33]. NGAL protein levels are
robustly increased in human AD postmortem brain
regions affected by AD pathology, particularly the
hippocampus [23]. Furthermore, increased plasma
NGAL levels were found in people with MCI [34].
In cerebrospinal fluid (CSF), NGAL levels were sig-
nificantly decreased in AD patients as well as in MCI
patients that later converted to AD, which mimics the
characteristically lowered CSF A levels in AD [23,
35]. We recently showed that plasma NGAL levels
are increased in depressed older persons [22]. In addi-
tion, plasma NGAL levels are significantly increased
in depressed elderly females with impaired recall
memory [36].
Cell culture experiments showed that NGAL is
increased in different brain cell types upon expo-
sure to A and stimulation of tumor necrosis factor-
receptor 1 (TNFR1), and sensitizes primary corti-
cal neurons and astrocytes to A- and oxidative
stress-induced cell death [23, 37, 38]. These effects
may in part be caused by silencing of neuropro-
tective tumor necrosis factor- receptor 2 (TNFR2)
signaling [23]. NGAL is significantly increased in
the hippocampus of mice following psychological
stress, where it reduces dendritic spine formation of
hippocampal neurons, potentially by inhibiting Akt
phosphorylation of the protein kinase B (PKB)/Akt
pathway [23, 33]. Furthermore, increased NGAL
aggravates neuroinflammation upon neuronal dam-
age and promotes the pro-inflammatory phenotypes
of astrocytes and microglia [39–41].
The above-mentioned studies indicate that NGAL
functions as a neuroinflammatory constituent that
is involved in the pathophysiology of both depres-
sion and AD, and might exacerbate AD pathology
in the presence of co-existing depression. Therefore
our objectives were (1) to investigate NGAL pro-
tein levels in serum, CSF, and human postmortem
brain tissue (nine different brain regions) of con-
trol subjects, AD–D, and AD+D patients, and (2) to
assess whether changes in brain NGAL levels cor-
relate with alterations in the protein expression of
its receptors, megalin and 24p3R. We hypothesize
that NGAL levels are increased in AD-related brain
regions in AD–D patients as compared to healthy
age-matched controls, and further increased in AD+D
patients in certain brain regions that are involved in
both depression and AD.
MATERIALS AND METHODS
Human samples
Human tissue samples (serum, CSF, and brain
tissue) from healthy controls, AD–D, and AD+D
patients were obtained from the Biobank of the Insti-
tute Born-Bunge (University of Antwerp, Belgium)
and stored at –80◦C until analysis. Informed con-
sent for behavioral assessments and tissue collection
was provided by all participants. Ethical approval for
human sample collection was granted by the Medical
Ethical Committee of the Middelheim General Hos-
pital (Antwerp, Belgium) (approval numbers 2805
and 2806). Participants who were known to suffer
from diseases that could influence NGAL levels, such
as renal failure and cancer, were excluded. In this
respect, C-reactive protein (CRP) levels were mea-
sured in serum by ELISA analysis (Abnova, KA0238,
performed according to the manufacturer’s proto-
col) (Table 1). Serum CRP levels in control patients
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Table 1
Patient demographics, behavioral and cognitive symptoms, and use of anti-depressant medication (administered no more than one day
before death)
Parameter
Serum Control (n = 40) AD – D (n = 40) AD + D (n = 40)
Gender, female, n (%) 20 (50) 20 (50) 20 (50)
Age (years), mean (SD) 78.33 (7.19) 79.50 (9.20) 79.35 (8.69)
CSDD scale, mean (SD) 2.83 (2.48) 3.80 (2.15) 11.05 (2.57)
MMSE, mean (SD) 28.00 (1.62) 14.97 (6.54) 12.54 (6.86)
Anti-depressant medication, n (%) 5 (12.5) 8 (20) 16 (40)
CRP (mg/L), mean (SD) 9.43 (19.24) 20.91 (32.38) 22.78 (36.02)
Cerebrospinal Fluid Control (n = 26) AD – D (n = 40) AD + D (n = 40)
Gender, female, n (%) 13 (50) 20 (50) 20 (50)
Age (years), mean (SD) 78.90 (5.74) 79.50 (9.20) 79.35 (8.69)
CSDD, mean (SD) N.D. 3.80 (2.15) 11.05 (2.57)
MMSE, mean (SD) N.D. 14.97 (6.54) 12.54 (6.86)
Anti-depressant medication, n (%) N.D. 8 (20) 16 (40)
Brain tissue Control (n = 19) AD – D (n = 19) AD + D (n = 21)
Gender, female, n (%) 7 (36.84) 7 (36.84) 8 (38.10)
Age (years), mean (SD) 73.04 (9.24) 83.25 (9.09) 77.74 (10.18)
Braak stage, mean (SD) 0.06 (0.25) 4.15 (1.02) 4.58 (1.12)
CSDD, mean (SD) N.D. 4.74 (1.88) 13.33 (4.52)
Anti-depressant medication, n (%) 4 (21.05) 3 (15.79) 10 (47.62)
AD–D, Alzheimer’s disease without co-existing depression; AD+D, Alzheimer’s disease with co-existing depression; n, number of patients;
SD, standard deviation; N.D., not determined; CSDD, Cornell Scale for Depression in Dementia; MMSE, Mini-Mental State Examination.
on average were below 10 mg/L, which is within
normal range for healthy adults, indicating that active
inflammation was not present in these participants
[42]. Analyses of variance showed that serum CRP
levels in AD patients were not significantly differ-
ent from those in control patients (F = 2.30, df = 2,
p = 0.11). Further details and inclusion criteria are
described by Vermeiren et al. [43, 44].
Brain tissue samples were collected from nine
different brain regions, including the hippocam-
pus, amygdala, thalamus, cerebellum, Brodmann
area (BA) 9 (BA9; dorsolateral prefrontal cortex),
BA10 (frontopolar cortex), BA11 (orbitofrontal cor-
tex), BA22 (superior temporal cortex), and BA24
(ventral/dorsal anterior cingulate cortex (ACC)).
Autopsy and collection procedures were performed
as described previously [43, 44]. Briefly, brain
autopsy was performed within 6 h after death of
consented patients, upon which the left hemisphere
was frozen at –80◦C for neurochemical analyses,
and the right hemisphere was formaldehyde-fixed for
neuropathological examination. Neuropathological
examination was performed as previously described
[44] using the criteria of, among others, Braak and
Braak and Montine et al. [2, 45]. Absence of AD
pathology was confirmed in all control brains used in
this study, and definite AD diagnosis was confirmed
in all AD brains (see Table 1 for Braak stages). No sig-
nificant vascular pathology was detected in the brains.
The frozen left hemisphere was routinely dissected
into 21 brain regions, following a standard procedure
[44]. The inclusion of the nine brain regions selected
for this study was based on their involvement in both
depression and AD.
Paired AD CSF and serum were not from the same
AD patients as those from whom brain tissue was
obtained. CSF and serum were from patients that had
a diagnosis ranging from probable to definite AD.
Numbers and demographic details of participants are
listed in Table 1.
Neuropsychiatric evaluation
For all patients, the Cornell Scale for Depression in
Dementia (CSDD) was used to distinguish between
AD–D and AD+D (see also Table 1). The CSDD
scale examines signs of major depression in demented
patients [46]. The presence of significant depressive
symptoms is suggested by a total score of 8 or more,
while scores above 18 are indicative of major depres-
sion [14]. For the current study, AD patients with a
CSDD score of ≥8 were classified as AD+D patients,
whereas patients with a CSDD score of <8 were
defined as non-depressed, AD–D patients.
Mini-Mental State Examination (MMSE) scores
were determined in all subjects from whom serum
was obtained, and in AD patients from whom
CSF was collected. In addition, the Middelheim
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Frontality Score (MFS) scale was included as a mea-
sure of frontal lobe features [47].
For the control patients from whom serum was
obtained, the time between behavioral scoring and
sampling of serum was on average 0.7 days (SD;
1.83 days), and the time between MMSE scoring and
sampling was 4.25 days (SD; 11.65 days). From AD
patients, serum and CSF were collected on average
0.36days(SD;1.41days)apartfrombehavioralrating.
ForADpatients fromwhombrain tissuewasobtained,
the average time from baseline or follow-up (n = 9)
behavioral scoring until time of death was 6.23 days
(SD;11.49).Nobehavioraldatawasobtainedfromthe
control subjects from whom brain tissue was received.
Measurement of NGAL with ELISA
NGAL in serum and CSF samples was quantified
via a sandwich ELISA (R&D Systems) according to
the manufacturer’s protocol, as described previously
[22, 23]. Serum was diluted 1 : 100, and CSF samples
were not diluted. The intra- and inter-assay coeffi-
cients of variation were 3% and 5%, respectively.
Western blot analyses of NGAL, megalin,
and 24p3R levels in brain tissue
Brain NGAL, megalin, and 24p3R levels were
determined by western blot as previously described
[23]. An NGAL antibody specifically directed against
human NGAL was used at a concentration of 1 : 600
(rat anti-human LCN2, MAB17571, R&D systems).
Both megalin (rabbit anti-megalin, Ab129198,
Abcam) and 24p3R (rabbit anti-24p3R, Ab124506,
Abcam) antibodies were used at 1 : 1000 dilution.
Actin served as internal standard to control for load-
ing variations and was used at 1 : 1000 000 dilution
(mouse anti-actin, 691002, ImmunO, MP Biomedi-
cals Inc.). Appropriate HRP-conjugated secondary
antibodies were used at a 1 : 5000 dilution (donkey
anti-rabbit, NA934, GE Healthcare; goat anti-mouse,
Sc-2005, SantaCruz Biotechnology; goat anti-rat,
112-035-003, Jackson ImmunoResearch Laborato-
ries Inc.). Examples of full western blots for NGAL,
24p3R, and megalin are shown in Supplementary
Figure 3.
Immunohistochemistry for ﬂuorescent double
stainings
Paraformaldehyde-fixed hippocampal brain tissue
from AD patients was used for immunofluorescent
double stainings. For double stainings of NGAL with
ionized calcium-binding adapter molecule 1 (Iba1)
and glial fibrillary acidic protein (GFAP), brain sec-
tions were cut from paraffin embedded tissue (10m
thick). These sections were deparaffinized before
start of the staining protocol. For double staining of
NGAL with neuronal nuclei (NeuN), brain sections
were obtained from frozen, non-paraffin embedded
tissue (16m thick). Sections were subjected to heat-
induced antigen retrieval with 10 mM sodium citrate
buffer (pH 6.0, no Tween) in the microwave. Tis-
sue was then blocked with 10% normal serum in
PBS+0.3% Triton X-100 for 1 h at room temperature,
and incubated with the primary antibody overnight at
4◦C. Primary antibodies were diluted in PBS+0.3%
Triton X-100, with 1% normal serum. The following
primary antibodies were used: anti-NGAL (R&D sys-
tems, MAB1757, 1 : 50 dilution), anti-Iba1 (Wako,
019-19741, 1 : 1000 dilution), anti-GFAP (Sigma
g3839, 1 : 1500 dilution), and anti-NeuN (Abcam,
Ab177487, 1 : 300 dilution). Subsequently, sections
were incubated with secondary antibodies for 1 h at
RT. Secondary antibodies were labelled with either
Alexa Fluor 488 (Abcam Ab150153 or Molecular
Probes A-21202, used at 1 : 400 dilution) or Cy3
(Jackson ImmunoResearch 712-165-150 or 711-165-
152, used at 1 : 700 dilution). Stainings were mounted
with Mowiol, and imaged with the Leica TCS SP8
microscope.
Statistical analysis
Analysis of variance (ANOVA) with Tukey post
hoc test for pair-wise comparisons was used to deter-
mine differences in NGAL protein levels between
healthy controls, AD–D, and AD+D patients. This
was followed by analyses of covariance (ANCOVA)
with Bonferroni post hoc test with CSF or brain
NGAL levels as dependent variable to analyze NGAL
levels between the studied groups, adjusted for age
and gender as confounding factors for CSF NGAL
levels, and age, gender, and use of anti-depressants
as confounding factors for brain NGAL levels. Due
to the limited number of brain tissue samples, boot-
strapping was used with 1000 bootstraps per sample
for analyses of brain tissues. Results were con-
sidered statistically significant when p-values were
<0.05. Pearson correlation was used to examine
the association between hippocampal NGAL lev-
els and the severity of depression, and associations
between NGAL, megalin, and 24p3R in the stud-
ied brain regions. A corrected p-value of less than
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0.006 was considered significant for multiple com-
parisons between NGAL, megalin, and 24p3R in
the nine studied brain regions. As the correlations
between the MFS with NGAL in the nine brain
regions were exploratory, p-values were not cor-
rected and p-values less than 0.05 were considered
significant. All analyses were conducted with SPSS
version 22.0.
RESULTS
NGAL levels in different brain regions of control,
AD–D, and AD+D patients
Mean NGAL/actin ratios in all nine investigated
brain regions are displayed in Fig. 1. The data
shown is not yet adjusted for age, sex, and use of
anti-depressants, which are potential confounding
factors. NGAL was ubiquitously expressed through-
out the healthy human brain. NGAL levels in the
hippocampus were higher in AD–D than in healthy
controls, and even higher in AD+D (Fig. 1A). After
adjustment for confounders (age, sex, and use of
anti-depressants), the increased NGAL levels as com-
pared to controls remained significant for AD–D
(p = 0.017) and AD+D (p = 0.003), but the differ-
ence between the AD–D and AD+D group was no
longer significant (p = 0.112). As depicted in Fig. 2,
hippocampal NGAL levels were found to be pos-
itively correlated with the severity of depression
(as measured by the CSDD depression score) in
all of the AD patients (r = 0.359, p = 0.027). The
amygdala contains higher NGAL levels in both
AD–D and AD+D patients as compared to con-
trols (Fig. 1B); these differences remained significant
(AD–D, p = 0.027; AD+D, p = 0.04 compared to
control) after adjusting for confounding factors.
NGAL in the thalamus showed a similar expres-
sion pattern to that found in the amygdala (Fig. 1C).
After adjustments for confounding factors, NGAL
remained significantly higher in AD–D (p = 0.002)
compared to controls. Furthermore, a distinct pat-
tern of NGAL levels was observed for BA9, BA10,
BA11, and BA24: NGAL levels were significantly
increased in AD–D patients compared to controls,
but were not different between controls and AD+D
patients and even significantly lower in AD+D
as compared to AD–D (Fig. 1D-G). For BA11,
these differences were, however, not significant, as
shown in Fig. 1F. Moreover, after adjusting for con-
founding factors, the differences in NGAL levels
between control and AD–D were as follows: BA9
(p = 0.029), BA10 (p = 0.073), BA11 (p = 0.098),
and BA24 (p = 0.05). Similarly, when comparing
AD–D and AD+D participants, adjustment for con-
founding factors gave the following results: BA9
(p = 0.029), BA10 (p = 0.040), BA11 (p = 0.112), and
BA24 (p = 0.069). In BA22 and the cerebellum, no
differences between the three groups were found
(Fig. 1H, I).
To assess to which brain cell types NGAL is
localized in the AD hippocampus, double stain-
ings between NGAL and markers for microglia
(Iba1), astrocytes (GFAP), and neurons (NeuN) were
performed (Fig. 3). Immunofluorescent stainings
showed that there is little co-localization for NGAL
with microglia (Fig. 3A-C) and neurons (Fig. 3G-I).
NGAL did co-localize with GFAP-positive astrocytes
(Fig. 3D-F).
NGAL levels in serum and CSF
Serum NGAL levels were not significantly dif-
ferent between the study groups (ANOVA, F = 0.26,
df = 2, p = 0.77) (Fig. 4A). There were, however, dif-
ferences between the studied groups in CSF NGAL
levels (ANOVA, F = 9.52, df = 2, p < 0.001). NGAL
levels were significantly lower in AD–D (p < 0.001)
and AD+D (p = 0.001) CSF compared to control CSF
(Fig. 4B). Further, analyses with ANCOVA (F = 9.30,
df = 2, p < 0.001) and Bonferroni post hoc test showed
that CSF NGAL levels remained significantly lower
in AD–D (p = 0.001) and AD+D (p = 0.001) after
including age and gender as covariates.
Megalin and 24p3R levels in different brain
regions
Megalin levels were significantly higher in the
amygdala of AD+D patients as compared to con-
trols (Fig. 5A); this remained significant (p = 0.022)
after adjusting for confounding factors (age, gen-
der, and use of antidepressant medication). A similar
pattern was found in BA11 (Fig. 5B), but this differ-
ence lost significance after adjusting for covariates
(p = 0.059). No differences in megalin levels between
the three groups were found in the other brain regions
(Supplementary Figure 1). Moreover, for 24p3R, no
differences between control, AD–D, and AD+D were
found for any of the studied brain regions (Supple-
mentary Figure 2).
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Fig. 1. NGAL levels in nine different brain regions of control, AD–D, and AD+D patients, as assessed by western blot. Brain regions included
(A) hippocampus, (B) amygdala, (C) thalamus, (D) BA9, (E) BA10, (F) BA11, (G) BA24, (H) BA22, and (I) cerebellum. Bars indicate
the mean ratio between NGAL and the internal control protein actin, ±SEM. AD–D, Alzheimer’s disease without co-existing depression;
AD+D, Alzheimer’s disease with co-existing depression; BA, Brodmann area.
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Fig. 2. Pearson correlation between hippocampal NGAL levels
and CSDD depression score, in all AD patients. r = 0.359 and
p = 0.027.
Correlation between brain NGAL, megalin,
and 24p3R in different brain regions
No significant correlations were found between
NGAL and 24p3R or megalin levels. Megalin and
24p3R levels were positively correlated in the hip-
pocampus (r = 0.510, p < 0.001) (Table 2).
Correlations between prefrontal NGAL levels
and frontal lobe features
NGAL levels in BA9, BA10, BA11, and BA24
were found to be inversely correlated with the MFS in
AD patients (Table 3). There were no significant cor-
relations between MFS scores and megalin or 24p3R,
in any of the studied brain regions.
DISCUSSION
This study shows the following three main find-
ings: (1) NGAL levels are significantly higher in
regions throughout the brain, which are commonly
affected by AD pathology; (2) NGAL levels were
significantly increased in the hippocampus in AD,
and even more so in AD with co-existing depression.
Hippocampal NGAL levels were positively corre-
lated with the severity of depression; (3) Surprisingly,
as compared to control patients, AD patients with
co-existing depression did not show higher NGAL
levels in the studied prefrontal cortical regions and
BA24.
NGAL in AD–D brains
We have previously shown that NGAL levels
were significantly higher in the entorhinal cortex
and especially the hippocampus of AD patients as
compared to age-matched controls, while cerebellar
NGAL levels remained unchanged [23]. Our current
observations confirm these previous findings. More-
over, the previous findings are complemented by the
novel findings of increased NGAL levels in several
other brain regions, including the prefrontal cortex,
which are known to be affected by AD [2, 48, 49].
Whether NGAL expression in the brain merely fol-
lows AD pathology or also precedes it remains to be
elucidated.
NGAL in AD+D brains
Consistent with our hypothesis, a comparison
between controls, AD–D, and AD+D patients showed
that hippocampal NGAL levels were higher in AD–D,
and even higher in AD+D patients, as compared to
controls. This may reflect aggravated hippocampal
A and tau pathology in AD+D versus AD–D as
described in literature [17, 18], which might con-
tribute to higher NGAL levels since A directly
stimulates the production of NGAL [38].
The prefrontal cortical regions BA9, BA10, and
BA11 and the anterior cingulate cortical area BA24
unexpectedly had lower NGAL levels in AD+D
compared to AD–D patients. Evidence exists of
dissimilarities between prefrontal cortex and hip-
pocampus in major depressive disorder that could
explain our findings. Circuitries involved in mood
regulation may be dysfunctional in late-life depres-
sion, due to disruptions in underlying white matter
tracts. Such mood-related connections also exist
between the hippocampus and prefrontal cortical
regions [50–55]. Immunohistochemical staining of
human AD postmortem brain tissue illustrated a
robust punctate and diffuse distribution of NGAL in
the cell bodies, axons, and dendrites of hippocampal
pyramidal neurons of the CA1 region [23]. Hypo-
thetically, hippocampal NGAL may normally be
transported via neuronal projections to prefrontal cor-
tical regions. Disruptions in such projections, which
may be present in co-existing symptoms of depres-
sion in AD, might therefore impair transport of
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Fig. 3. Double stainings for NGAL with Iba1 (A-C), GFAP (D-F), and NeuN (G-I), in AD hippocampal human brain sections. Scale bar:
25m.
Table 2
Correlations between brain levels of NGAL, megalin, and 24p3R
BA 9 BA 10 BA 11 BA 22 BA 24 Cerebellum Amygdala Hippocampus Thalamus
1 r = –0.153 r = 0.016 r = 0.117 r = 0.327 r = –0.096 r = 0.065 r = –0.063 r = 0.159 r = 0.369
p = 0.259 p = 0.905 p = 0.406 p = 0.026 p = 0.490 p = 0.624 p = 0.659 p = 0.266 p = 0.009
2 r = –0.155 r = 0.005 r = –0.264 r = 0.001 r = –0.193 r = 0.037 r = –0.035 r = –0.057 r = 0.049
p = 0.254 p = 0.968 p = 0.054 p = 0.995 p = 0.161 p = 0.783 p = 0.814 p = 0.685 p = 0.733
3 r = 0.363 r = 0.238 r = 0.148 r = 0.206 r = 0.338 r = 0.359 r = 0.000 r = 0.510 r = 0.369
p = 0.006 p = 0.077 p = 0.296 p = 0.179 p = 0.012 p = 0.006 p = 0.999 p< 0.001 p = 0.008
Pearson correlations in all nine brain regions between: 1) NGAL with megalin (whole population), 2) NGAL with 24p3R (whole population),
and 3) Megalin with 24p3R (whole population). Significant correlations are written in bold. BA, Brodmann area. For correction of multiple
comparisons, a p-value of less than 0.006 was considered significant.
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Fig. 4. NGAL levels in human (A) serum and (B) CSF of control, AD–D, and AD+D patients, as measured by ELISA. Bars indicate mean
protein concentration in ng/ml (for serum) and pg/ml (for CSF). Error bars represent SEM. **p = 0.001, ***p < 0.001. AD–D, Alzheimer’s
disease without co-existing depression; AD+D, Alzheimer’s disease with co-existing depression.
Fig. 5. Megalin levels in (A) BA11 and the (B) amygdala of control, AD–D, and AD+D patients. Bars indicate the mean megalin/actin
ratio, ±SEM. AD–D, Alzheimer’s disease without co-existing depression; AD+D, Alzheimer’s disease with co-existing depression; BA,
Brodmann area.
Table 3
Correlations between the Middelheim Frontality score (MFS) and AD brain levels of NGAL, megalin, and 24p3R
BA 9 BA 10 BA 11 BA 22 BA 24 Cerebellum Amygdala Hippocampus Thalamus
1 r = –0.373 r = –0.452 r = –0.375 r = –0.057 r = –0.399 r = –0.018 r = –0.057 r = 0.078 r = 0.152
p = 0.023 p = 0.005 p = 0.022 p = 0.736 p = 0.016 p = 0.913 p = 0.754 p = 0.648 p = 0.376
2 r = 0.028 r = 0.050 r = 0.174 r = 0.079 r = 0.001 r = –0.025 r = 0.210 r = 0.047 r = –0.044
p = 0.872 p = 0.772 p = 0.309 p = 0.651 p = 0.996 p = 0.882 p = 0.233 p = 0.788 p = 0.803
3 r = 0.044 r = 0.009 r = 0.292 r = 0.251 r = 0.131 r = 0.035 r = –0.155 r = –0.160 r = –0.069
p = 0.797 p = 0.818 p = 0.084 p = 0.141 p = 0.447 p = 0.833 p = 0.413 p = 0.487 p = 0.693
Pearson correlations in all nine brain regions between: 1) NGAL with MFS (only in AD patients), 2) Megalin with MFS (only in AD patients),
and 3) 24p3R with MFS (only in AD patients). Significant correlations are written in bold. BA, Brodmann area.
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NGAL to prefrontal regions, and lead to reduced
NGAL levels as shown in this study. This hypoth-
esis is further supported by the finding that prefrontal
NGAL levels negatively correlate with the MFS
score. The MFS provides a measure of frontal
lobe features, with a higher score indicating greater
abnormalities in frontal lobe functioning [47]. Inter-
estingly, it has been previously reported that MFS
scores are positively correlated with severity of
depressive symptoms in AD [56], which we also
found in patients in this study (data not shown). Taken
together, our current results support the association
between higher MFS scores and depression, and sug-
gest that frontal lobe changes (which may be involved
in the pathology of depression) may be linked with
lower NGAL levels in the prefrontal cortex. How-
ever, due to the exploratory nature of the correlations
between the MFS with NGAL, these findings should
be interpreted with caution.
Of interest, there may be other factors that,
like NGAL, show lower levels in AD+D patients
than in AD–D patients, in the prefrontal cortex.
In a recent study by Vermeiren et al. [44], the
levels of monoamines and their metabolites were
determined in the same human brain samples as inves-
tigated in the current study. Interestingly, the levels
of 3-methoxy-4-hydroxyphenylglycol (MHPG), the
metabolite of norepinephrine (NE), were found to be
significantly decreased in BA9 and BA10 in AD+D
patients as compared to AD–D patients. It was sug-
gested by Vermeiren et al. that these lower prefrontal
MHPG levels in AD+D patients may be due to
altered norepinephrinergic neurotransmission in the
prefrontal cortex, caused by a more severe neurode-
generation of the locus coeruleus in AD+D patients.
The locus coeruleus is the primary center of NE
synthesis in the brain, and has strong connections
with the prefrontal cortex. Although the lower pre-
frontal NGAL and MHPG levels in AD+D patients
as compared to AD–D patients probably have differ-
ent underlying mechanisms, it is interesting to see that
they share this feature. Furthermore, it might be that
NGAL expression may in part be induced via NE.
Although not shown in brain cells, it was reported
that NE treatment of adipocytes causes a significant
increase in intracellular NGAL levels [57].
NGAL levels in serum and CSF
Corresponding to our previous findings [23], we
did not find significant changes in serum NGAL lev-
els between the studied groups. As shown by [34],
it may be that increased serum NGAL levels appear
especially in early stages of AD. Moreover, although
it was previously shown that plasma NGAL levels
were elevated in elderly depressed patients [22], this
effect may be lost in AD+D patients.
Lower CSF NGAL levels in AD are in accor-
dance with our previous findings [23]. The decreased
NGAL levels in CSF of AD patients might in part
be explained by lower megalin expression in the
choroid plexus of AD patients [58]. Since megalin
in the choroid plexus may transport NGAL from the
brain into the CSF, lower megalin levels therefore
can result in less NGAL clearance from the brain,
causing increased brain NGAL levels and decreased
CSF NGAL levels in AD. This potential explanation
is supported by the findings that megalin can also
transport A from the brain to CSF, and that signif-
icantly reduced CSF A levels are characteristic for
AD [23, 35, 58–63]. Our findings further show that
CSF NGAL levels are not affected by the presence of
co-existing depression in AD.
Megalin and 24p3R
The neurobiological functions of increased
megalin levels in BA11 and the amygdala, shown in
this study, are unclear. Megalin is expressed through-
out the brain, by different cell types like neurons,
microglia, astrocytes, and endothelial cells. It was
reported that neuronal and astrocytic megalin may
play an important role in modulating A-mediated
neurotoxicity, by indirectly reducing A secretion
into the extracellular space [64]. Previous studies
showed that megalin expression is decreased in the
choroid plexus of AD patients [58]. Our findings indi-
cate that this is not the case for the brain regions in
this study.
For 24p3R, no differences between control, AD–D,
and AD+D were found for any of the studied brain
regions. In addition, 24p3R and NGAL levels did
not correlate in any region. Brain 24p3R is mostly
expressed by neurons and endothelial cells, with high
expression in the choroid plexus [32]. It is involved
in endocytic iron delivery, and is known to medi-
ate apoptosis upon binding of an iron-free form of
NGAL [28]. Moreover, iron-free NGAL decreases
hippocampal spine density in cell culture [33]. The
effects of NGAL via 24p3R in neurons may depend
on the levels of iron-free NGAL rather than the
expression levels of the receptor itself.
Interestingly, despite a lack of strong correlation
with NGAL levels for both megalin and 24p3R, the
D.W. Dekens et al. / Neuroinﬂammation in AD and Depression 773
Fig. 6. Known and potential triggers of NGAL expression in the hippocampus, with effects of hippocampal NGAL that may hypothetically
contribute to pathophysiological processes of AD and depression.
receptors positively correlated with one another in
the hippocampus. Mechanisms involved in the reg-
ulation of the expression of megalin and 24p3R are
still unknown. However, A may to a certain degree
play a role in the regulation of both receptors by
increasing their mRNA levels in cultured neurons and
astrocytes [38].
Strengths and limitations
Behavioral assessments were performed close to
the patients’ death, increasing the reliability of
these measurements. Furthermore, NGAL is a stable
marker since it is resistant to proteolytic degrada-
tion and possesses great storage stability [65, 66]. A
few limitations of this study should be acknowledged.
Symptoms of depression were not evaluated in con-
trol subjects from whom brain tissue was obtained.
Thus presence of depressive symptoms cannot be
excluded with certainty. However, the control group
of this study did not have chronic diseases and use of
anti-depression medication was low (Table 1). Four
of the control patients from whom brain tissue was
studied had received an anti-depressant on the day of
or the day before death. For two of these patients,
there was no clinical indication of depression. Of
the other two, one patient had a reactive depression
after loss of his wife one month before, and another
patient suffered pain and was treated with an anti-
depressant. Furthermore, behavioral assessments of
control patients from whom CSF was obtained, were
not available.
Another significant limitation of this study is the
realization that depressive symptoms are variable
in time. Even though the last neuropsychological
assessment was done very shortly before the time
of death (on average 6.23 days before death, for
patients from whom brain tissue was obtained), it
is possible that depressive feelings earlier in life or
around time of death may have been different from
depressive symptoms around the time of the CSDD
assessment. From the 9 patients with whom follow-up
neuropsychological assessment was done, 6 showed a
stable CSDD score over time, while 2 patients showed
a clear increase in CSDD rating in subsequent follow-
up assessments. Yet, even when CSDD scores would
vary to some extent after the last neuropsycholog-
ical assessment, the characterization of the AD–D
and AD+D groups may remain correct. Namely, the
AD+D and AD–D groups had CSDD scores that were
either relatively/very high (average CSDD score of
13.3, depressed) or very low (average CSDD score
of 4.7, non-depressed), and thus safely distant from
the cut-off CSDD score that was set at 8.
Moreover, we did not have information about the
life-long history of depression in the studied patients.
In future studies it may be of interest to compare
patients with a history of multiple/early-onset depres-
sions, with patients that for example suffered a single
depression, or depression that had its onset in late
life. For the current study, it could be said that
we have looked at depressive ‘states’ rather than
‘traits’.
Additionally, while the results raise multiple mech-
anistic questions concerning NGAL regulation and
effects of NGAL, molecular and cellular mechanisms
were not investigated in this study. As such, the cur-
rent results cannot imply a causal role of NGAL
in AD–/+Depression, and future research has to be
done to further determine the importance of NGAL in
development and progression of AD–/+Depression.
Another aspect that would be of interest to inves-
tigate further is the cell type(s) by which NGAL
is produced and secreted. We hypothesize that this
may be highly dependent on the type of trigger
that is present (and possibly the brain region that
is involved): it seems that in neurodegenerative con-
ditions astrocytes are the main producers of NGAL
[67], while stimuli such as psychological stress might
mostly trigger NGAL expression in neurons [33]. In
the current study, we found co-localization between
NGAL and the astrocyte marker GFAP in the AD hip-
pocampus, and little co-localization between NGAL
and markers for microglia and neurons (Fig. 3).
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It should be noted, however, that these stainings
cannot distinguish whether NGAL positive cells are
the source of the detected NGAL, or whether the cells
have taken up NGAL that was secreted from other
cells.
Conclusion
This study shows that NGAL levels are increased in
the AD brain, in multiple regions associated with AD
pathology. Hippocampal NGAL levels are increased
when symptoms of depression are present in AD, and
are positively correlated with the severity of depres-
sion in AD patients. NGAL is involved in several
mechanisms that can contribute to neuronal dysfunc-
tion and cell death, as described in the introduction.
Thus, increased hippocampal NGAL levels in AD,
especially in AD+D, could aggravate the pathophys-
iology of AD (summarized in Fig. 6). Differential
expression levels of NGAL in the prefrontal cortex of
AD–D versus AD+D patients indicate that there are
differences in neuroinflammatory regulation in AD
with and without co-existing symptoms of depres-
sion. Moreover, this study provides new insights
into NGAL as neuroinflammatory constituent
underlying co-existing symptoms of depression
in AD.
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